Swedish Orphan Biovitrum AB Aktie
| 36,92EUR | 0,68EUR | 1,88% |
WKN DE: A0LA5K / ISIN: SE0000872095
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 1 559 | 1 556 | 1 772 | 1 840 | 1 888 |
| Umsatz pro Mitarbeiter in Mio. EUR | 9,96 | 12,08 | 12,49 | 14,15 | 14,96 |
Bilanz (in Mio. SEK) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 8 778 | 11 211 | 12 671 | 13 162 | 14 528 |
| Summe Anlagevermögen | 39 883 | 41 285 | 61 356 | 62 282 | 52 906 |
| Summe Aktiva | 48 661 | 52 496 | 74 027 | 75 444 | 67 434 |
Bilanz (in Mio. SEK) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 25 458 | 25 971 | 40 160 | 35 149 | 29 711 |
| Summe Eigenkapital | 23 203 | 26 525 | 33 867 | 40 295 | 37 723 |
| Summe Passiva | 48 661 | 52 496 | 74 027 | 75 444 | 67 434 |
Adresse
| Tomtebodavägen 23A, 112 76 Solna | |
| Telefon | +46 (8) 697-20-00 |
| Fax | +46 (8) 697-23-30 |
| Internet | http://www.sobi.com |
Management
|
Armin Reininger
Head-Medical & Scientific Affairs |
|
Christine Wesström
Head-Technical Operations |
|
Christophe Bourdon
Director |
|
Daniel Rankin
Head-Strategy & Corporate Development |
|
David D. Meek
Chairman |
|
Filippa Stenberg
Independent Director |
|
Gerard Tobin
Head-Investor Relations |
|
Guido Oelkers
President & Chief Executive Officer |
|
Henrik Stenqvist
Chief Financial Officer |
|
Iris Löw-Friedrich
Director |
|
Katy Mazibuko
Director |
|
Lena Bjurner
Head-Human Resources |
|
Lydia Abad-Franch
Chief Medical Officer, Head-Research & Development |
|
Mahmood Ladha
Head-Strategic Transformation Operations |
|
Mats Lek
Director |
|
Norbert Oppitz
Head-International |
|
Pablo de Mora
Head-Global Marketing & Access |
|
Per Richard Torbjörn Hallberg
General Counsel & Head-Legal Affairs |
|
Staffan Schüberg
Independent Director |
|
Sven Anders Ullman
Director |
|
Zlatko Rihter
Director |